好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Evaluation of Clinical and Radiologic Relapses Around Nonviable Pregnancies in Women with Multiple Sclerosis
Multiple Sclerosis
P10 - Poster Session 10 (5:00 PM-6:00 PM)
1-003
To evaluate Multiple Sclerosis (MS) relapses/MRI activity around nonviable pregnancy loss.
MS predominantly affects women of childbearing age. Research suggests MS does not increase miscarriage rates (beyond the general population’s 15-20% in first trimester), however, data remains limited on MS outcomes related to nonviable pregnancy loss. Specifically, clinical and radiographic relapses after miscarriage and the influence of pre-conception disease-modifying therapies (DMT) on relapses has not been thoroughly studied.
Retrospective chart review was conducted at University of Colorado focusing on women with MS (wwMS) who experienced documented pregnancy loss between 2013-2023. This included spontaneous abortions, elective terminations, and ectopic pregnancies. Only those with documented neurologic care for the year before conception and the year after were included. Patients with incomplete data were excluded.
Preliminary analysis identified 16 wwMS and 18 nonviable pregnancies. Among them, 94% had relapsing-remitting MS diagnosis, with an average diagnosis duration of 8.4 years prior to conception. The cohort was predominantly Caucasian (81%) and non-Hispanic (87.5%), with an average conception age of 33.3 years. Of the 18 nonviable outcomes, 67% were spontaneous abortions, occurring at an average of 7.31 weeks. Other outcomes included ectopic pregnancies (17%), elective terminations due to genetic disorders (11%), and one molar pregnancy (5%). Half were on anti-CD20 therapy pre-conception, noting that 48% of all childbearing wwMS are on anti-CD20 therapies in our clinic. There were four clinical relapses in the year prior to conception, but none occurred during pregnancy or within the postpartum year. Asymptomatic radiologic changes were observed in 17% of postpartum MRIs.
Findings suggest spontaneous abortion is the most common nonviable pregnancy outcome among wwMS, aligning with general population trends. Postpartum relapse rates were lower than pre-conception rates, with minimal radiologic changes noted. Given the small sample size, further analysis with additional participant recruitment is planned and will be presented.
Authors/Disclosures
Elle Wade, MD
PRESENTER 		The institution of Dr. Wade has received research support from National Multiple Sclerosis Society .
Enrique Alvarez, MD, PhD (University of Colorado) Dr. Alvarez has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Alvarez has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Alvarez has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Alvarez has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Alvarez has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Alvarez has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene/BMS. The institution of an immediate family member of Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon.
Anna Shah, MD (University of Colorado, Neurology Dept) The institution of Dr. Shah has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. The institution of Dr. Shah has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. The institution of Dr. Shah has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. The institution of Dr. Shah has received research support from Rocky Mountain MS Center. The institution of Dr. Shah has received research support from Genentech/Roche. Dr. Shah has received personal compensation in the range of $500-$4,999 for serving as a 好色先生al Speaker with Rocky Mountain MS Center.